Evaluation of the 4-French Pulsar-18 Self-expanding Nitinol Stent in Long Femoropopliteal Lesions.
OBJECTIVE
To evaluate the patency and the freedom of target lesion revascularization of the 4-French Pulsar-18 self-expandable (SE) nitinol stent for the treatment of long femoropopliteal occlusive disease in a two-center, prospective, all-comers registry with a follow-up period of 12 months.


METHODS
This registry enrolled 36 patients with symptomatic femoropopliteal long lesions for recanalization and implantation of the 4-French Pulsar-18 SE nitinol stent. Routine follow-up examination including duplex ultrasound was performed after 6 and 12 months. Primary patency was defined as no binary restenosis on duplex ultrasound (Peak systolic velocitiy ration (PSVR) <2.5) and no target lesion revascularization was performed within 12 months' follow-up. No drug-eluting devices were allowed in this registry.


RESULTS
Average lesion length of the femoropopliteal segment was 182.3 ± 51.8 mm. Mean stent implantation length was 181.5 ± 35.4 mm. Total occlusion was present in 46 of the 48 (95.8%) treated lesions. Involvement of popliteal segment I-III was present in 3 (6.3%) lesions. The primary patency after 6 and 12 months was 87.5% and 85.4%, respectively. The clinically driven overall freedom from target lesion revascularization (fTLR) was 89.6% after 6 months and 87.5% after 12 months. ABI, pain-free walking distance and Rutherford category, all improved significantly (P < 0.001) after 6 and 12 months. The primary patency rate in patients with diabetes (P = 0.18) and renal insufficiency (P = 0.3) was not significantly lower as compared to the overall primary patency.


CONCLUSIONS
In this two-center, all-comers registry, the use of the Pulsar-18 SE nitinol stent for endovascular intervention of femoropopliteal disease with a mean lesion length of 182.3 ± 51.8 mm showed promising primary patency and fTLR rates after 6 and 12 months. Diabetes and renal insufficiency had no negative impact on the patency rate.
Klinikum Arnsberg, Vascular Centre, Arnsberg, Germany.
Michael
M
Lichtenberg
Katholisches Klinikum Essen, Cardiovascular Clinic, Essen, Germany.
Birgit
B
Hailer
Katholisches Klinikum Essen, Cardiovascular Clinic, Essen, Germany.
Matthias
M
Kaeunicke
Klinikum Arnsberg, Vascular Centre, Arnsberg, Germany.
Wilhelm-Friedrich
WF
Stahlhoff
Klinikum Arnsberg, Vascular Centre, Arnsberg, Germany.
Dirk
D
Boese
Klinikum Arnsberg, Vascular Centre, Arnsberg, Germany.
Frank
F
Breuckmann
4-French device; device evaluation; endovascular therapy; self-expanding nitinol stent; superficial femoral artery